CeQur Corp., which has its U.S. headquarters in Marlborough, has received CE Mark approval for its lead product, which provides three days of consistent delivery of insulin to people with type 2 diabetes.
Read more
CeQur’s insulin delivery device approved in Europe for TII
Posted in Glucose & Insulin